Recent data suggest that Lecanemab , a investigational monoclonal antibody , has the potential to slow the development of preclinical dementia . This medication targets removing amyloid deposits from https://bookmark-dofollow.com/story28149533/donanemab-an-promising-novel-dementia-approach